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Abstract
Cutaneous malignant melanoma (CMM) is the deadliest form of skin cancer and clinically challenging due to its propensity
to develop therapy resistance. Reactive oxygen species (ROS) can induce DNA damage and play a significant role in
CMM. MTH1 protein protects from ROS damage and is often overexpressed in different cancer types including CMM.
Herein, we report that MTH1 inhibitor TH1579 induced ROS levels, increased DNA damage responses, caused mitotic
arrest and suppressed CMM proliferation leading to cell death both in vitro and in an in vivo xenograft CMM zebrafish
disease model. TH1579 was more potent in abrogating cell proliferation and inducing cell death in a heterogeneous co-
culture setting when compared with CMM standard treatments, vemurafenib or trametinib, showing its broad anticancer
activity. Silencing MTH1 alone exhibited similar cytotoxic effects with concomitant induction of mitotic arrest and ROS
induction culminating in cell death in most CMM cell lines tested, further emphasizing the importance of MTH1 in CMM
cells. Furthermore, overexpression of receptor tyrosine kinase AXL, previously demonstrated to contribute to BRAF
inhibitor resistance, sensitized BRAF mutant and BRAF/NRAS wildtype CMM cells to TH1579. AXL overexpression
culminated in increased ROS levels in CMM cells. Moreover, silencing of a protein that has shown opposing effects on cell
proliferation, CAV-1, decreased sensitivity to TH1579 in a BRAF inhibitor resistant cell line. AXL-MTH1 and CAV-1-
MTH1 mRNA expressions were correlated as seen in CMM clinical samples. Finally, TH1579 in combination with BRAF
inhibitor exhibited a more potent cell killing effect in BRAF mutant cells both in vitro and in vivo. In summary, we show
that TH1579-mediated efficacy is independent of BRAF/NRAS mutational status but dependent on the expression of AXL
and CAV-1.
Introduction
Cutaneous malignant melanoma (CMM) is responsible for
most number of skin cancer related deaths [1]. Since the
discovery of the role of MAPK signaling pathway in mel-
anoma genesis, several BRAF, and MEK inhibitors (BRAFi
and MEKi) have been approved and used to treat the ~50%
of patients who have CMM harboring BRAFV600 muta-
tions. Treatment efficacy to MAPK pathway targeting
therapy of advanced BRAF-mutated CMM is high, but often
not long-lasting due to resistance development [2]. A more
comprehensive understanding of the immune system in
recent years has led to the development of checkpoint
inhibitors and has in many cases become first line treatment
with long-term effects observed for only a subset of the
patients [3, 4]. Hence there is still an unmet need for finding
alternative treatment options.
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Recent work suggests that CMM to some extent is a
Reactive oxygen species (ROS) driven tumor as CMM cells
exhibit high levels of ROS and ROS-induced DNA damage
that may cause genetic alterations [5]. Accumulating evi-
dence illustrates a link between MAPK signaling pathway,
ROS, and DNA damage responses [7]. BRAFi treatment
has been shown to induce ROS [6], indicating that ROS
may play a role in the pharmacological response of BRAFi
and in the development of resistance to the treatment [7].
Thus, ROS can promote cancer development and cancer cell
survival [8–10], but interestingly also suppress tumor
growth through induction of apoptosis and senescence via
DNA damage [11].
DNA repair is a safeguard for protecting cells against the
deleterious effects of ROS. Tumor cells often upregulate
several DNA repair proteins, one of them being MTH1, to
maintain the genomic integrity. MTH1 sanitizes the oxi-
dized dNTP pool by hydrolyzing harmful oxidative stress
induced 8-oxo-dGTP, thus preventing its incorporation into
DNA [12]. MTH1 has been shown to be upregulated in a
number of cancer types including CMM [13–15]. Although
tumor cells have elevated levels of MTH1, normal cells are
less dependent on it [16]. We and others [16, 17] hypo-
thesized that the upregulated level of MTH1 is a salvage
pathway for the cancer cell to survive and escape the ele-
vated ROS-induced oxidative damage and apoptosis/
senescence. However, the pharmacology and biology of
MTH1 and its inhibitors seems to be more complex than we
originally reported, since other groups developed non-
cytotoxic MTH1 inhibitors [18], while also additional
cytotoxic MTH1 inhibitors have been reported [19]. Further
work is needed to help refine our understanding in this area.
Wang et al. [15] demonstrated that silencing MTH1 made
BRAF mutant CMM cells more susceptible to oxidative
stress induced apoptosis.
Resistance to BRAFi has been associated with reactiva-
tion of the MAPK pathway stemming from upregulation of
RTKs such as AXL [20–23], which has been associated with
resistance to DNA damaging therapies [24]. The scaffolding
protein caveolin-1 (CAV-1) has also been associated to drug
resistance [25] and to integrate transduction of multiple
signaling including MAPK cascade [26].
In this study we investigated the cytotoxic potential of
TH1579 in CMM cells. Using FACS and time lapse we
were able to show induction of cell death and mitotic arrest
upon treatment with TH1579. AXL and CAV-1 played a
role in mediating TH1579 sensitivity. AXL-CAV-1 and
MTH1 are correlated, which was further validated in a
CMM patient cohort. Lastly, we show that combining
BRAFi with TH1579 was more effective in killing BRAF
mutant CMM cells. Our study highlights novel mechanisms
underlying TH1579-mediated cytotoxicity.
Material and methods
Clinical samples
Tumors from 32 CMM patients have previously been
sampled (fresh frozen core or fine needle aspirates) prior to
onset of treatment with MAPK targeting therapy or
checkpoint inhibitors and from five of the patients a sample
was collected during treatment from the same tumor.
Twenty of the patients were male and twelve female.
Median age of the patients was 66 years (range 42–86
years). The CMM were classified as stage IV M1a (n= 3),
M1b (n= 5), and M1c (n= 24). This study has been
approved by the regional ethics committee in Stockholm,
Sweden and has been conducted in accordance with the
ethical principles given in the Helsinki Declaration.
Informed consent was obtained from all the patients.
Cell lines and reagents
Cell culture
A375PR1 and A375VR4 were BRAFi resistant cell lines
derived from A375 American Type Culture Collection
(ATCC), where A375PR1 was induced with PLX4720 and
A375VR4 was induced with vemurafenib [27]. NRAS
mutant SkMel2 (Q61R) was obtained from ATCC, whereas
ESTDAB102 (Q61R), ESTDAB149 (Q61R), and BRAF/
NRAS wildtype (WT) cell lines ESTDAB105, ESTDAB138
were obtained from European Searchable Tumor Line
Database and Cell Bank (ESTDAB). For all experiments,
CMM patient-derived cell lines 159-PRE (pretreatment
short-term patient-derived cell line generated in house ori-
ginating from fine needle aspirates) were cultured in
DMEM. BRAF mutant cell lines were cultured in MEM
supplemented while the NRAS and BRAF/NRAS WT cell
lines were cultured in RPMI-1640. For co-cultures, spher-
oids, shMTH1 lines, cell lines generated with histone H2B
tags and in vivo transplants all cells were cultured in
DMEM. All cell lines were cultured as per the manu-
facturer’s guidelines (Thermo scientific) and confirmed to
be mycoplasma free using LookOut Mycoplasma PCR
detection kit (Sigma-Aldrich, Stockholm, Sweden).
Florescent labeling of cells
Using lentiviral transfection with pLenti-CMV-blast plas-
mids, A375 and SkMel2 cells were transfected with eGFP,
A375VR4, and ESTDAB102 cells with mTagBFP and
ESTDAB105 cells with mKO2. Stable cells were gener-
ated by antibiotic selection with 4 µg/mL blasticidin for
7 days.
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H2B cells
A375 and A375VR4 cells were transfected by lentivirus
using the H2b-GFP pLenti-CMV hygro plasmid. Stable
cells were generated by antibiotic selection with 400 µg/mL
hygromycin for 7 days.
Plasmids, cell lines, siRNA, and shRNA
All CMM cells used for in vivo zebrafish injections were
stably expressing tdTomato and luciferase or eGFP, and all
shMTH1 cell lines were generated by a lentivirus-based
approach using the vector #32904, #17477 (Addgene) for
in vivo injections and Ginseng vector [28] for
shMTH1 cells. To select cells successfully transfected with
the shRNA vector, puromycin at 4 µg/mL was used for
7 days. To induce the shRNA expression, cells were treated
with doxycycline at 1 µg/mL for 5–6 days. All siRNA and
overexpression plasmids were transfected using Lipofecta-
mine 2000 (Sigma-Aldrich Chemie Gmbh, Munich, Ger-
many) according to the manufacturer’s recommendations.
pBluescript PMS2 was a gift from Bert Vogelstein
(Addgene #16457), pX1 was a gift from Monica Hollstein
(Addgene #46848), pIRES-EGFP- puro was a gift from
Michael McVoy (Addgene #45567) and pIRES –puro2
AXL was gift from Aaron Meyer (Addgene #65627). H2b-
GFP was subcloned by PCR into the pENTR1A-GFP-N2
plasmid (Addgene #19364) at the HindII and BamH1
restriction sites. The H2b-GFP pENTR1A plasmid was
verified by sequencing and H2b-GFP was shuttled into the
pLenti-CMV hygro DEST plasmid (Addgene #17454) by
LR clonase. mTagBFP2-pENTR1A vector were generated
by subcloning the mTagBFP2 ORF into the pENTR1A no
ccDB (Addgene #17398) vector by PCR using the XhoI and
XbaI restriction sites. pLENTI-CMV-blast vectors with
either mTagBFP2, eGFP or mKO2 were generated by
shuttling the mTagBFP2-pENTR1A, pENTR1A-GFP-N2,
and mKO2-N1 vectors into the pLenti-CMV-blast DEST
vector using LR clonase. pENTR1A-GFP-N2 (FR1),
pENTRIA no ccDB (w48-1), and pLenti-CMV Hygro
DEST (w117-1) were gifts from Eric Campeau and Paul
Kaufman. mTagBFP2-pBAD was a gift from Michael
Davidson (Addgene plasmid #54572). mKO2-N1 was from
Michael Davidson and Atsushi Miyawaki (Addgene plas-
mid #54625).
In vivo transplantation, drug treatment, and
luciferase measurement
All cell cultures were harvested 1 h prior to transplantation
into zebrafish embryos. For a detailed description on pre-
paration of cells cultures, please view respective reference
[29]. Directly before transplantation, a highly concentrated
cell suspension was loaded into nonfilament microcapillaries
(World Precision Instruments) and ~100 cells were injected
into the blastula of zebrafish embryos at 2 h post fertiliza-
tion. Transplanted embryos were transferred into E3 medium
in a 10 cm culture dish and incubated at 33 °C. The next day,
embryos were screened for successful transplantation,
dechorionized using Pronase (Sigma) and distributed into
six-well plates (25 embryos/well) in a total volume of 3 mL
E3 medium containing 25 mM HEPES. MTH1 inhibitor
TH1579 (dissolved in DMSO to 10mM) was added directly
to the medium to a final concentration of 20 or 40 μM.
DMSO was used as control. For combination experiments,
the embryos were divided into four groups (DMSO control,
Vemurafenib (10 µM), TH1579 (20 µM) and combination).
During treatment, embryos were incubated at 33 °C until
individual tumor size detection by luminescence measure-
ment. After drug exposure, single zebrafish embryos were
transferred into opaque 96-well plates (Perkin Elmer) and
incubated for 30 min in lysis buffer (10% glycerol, 1%
Triton X-100, 1 mM DTT, pH 7.8). An equal amount of
substrate solution (1 mM DTT, 1 mM ATP, 0.3 mg/mL D-
luciferin, pH 7.8) was added for 5 min before measurement
of luminescence (Hidex Sense). For every animal experi-
ment conducted, 5–10 embryos were used per group to
ensure statistical power. For the combination studies, only
animals that had tumors above the median value for that
group were included in the analysis. For all other studies, all
animals were included. Zebrafish embryos were randomized
into different treatment groups at the start of the treatment.
No blinding was performed.
Flow cytometry
Fluorescence signal for Annexin V and PI-staining (Sigma-
Aldrich Chemie Gmbh, Munich, Germany), or Andy Fluor
647 Annexin V (BioCat Gmbh Heidelberg, Germany) for
comparing sets between co-culture and single culture
experiments using fluorescently labeled cells was measured
by flow cytometry (Novocyte 3000). A minimum of 10,000
events were measured using polygonal gating to exclude
debris. Fluorescence intensity was analyzed using
Novoexpress software (ACEA Biosciences, San Diego, CA,
USA) to determine induction of apoptosis and necrosis.
Cell cycle analysis
For cell cycle analysis, 100,000 cells/well were plated
overnight in 12-well plates, treated with either DMSO or
0.9 µM TH1579 for 24 h. The cells were then trypsinized,
harvested, and fixed in 4% buffered formaldehyde for 18 h
at room temperature, followed by fixation in 95% ethanol
for 1 h, and, finally, rehydrated in distilled water for 1 h.
After treatment with subtilisin Carlsberg solution (0.1%
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Sigma protease XXIV. 0.1 M Tris, and 0.07M NaCl (pH
7.2)) and staining with DAPI-Sulforhodamine solution
(8 µM DAPI, 50 µM sulforhodamine 101, 0.1 M Tris, and
0.07M NaCl (pH 7.5)), samples were analyzed using a
LSRII flow cytometer (Becton Dickinson), equipped with a
UV laser. DAPI fluorescence was measured above 435 nm.
Cell nuclei sub-G1 DNA content served as indicators of
apoptotic cell death. The ModFit program for cell cycle
analysis (Verity software house) was used for histogram
analysis. The number of nuclei/histogram was 10,000.
2D proliferation assay
For calculating the synergy index scores for the drug
combination experiments, 800–1000 cells/well were plated
overnight in a 384-well plate and DMSO as control or drugs
were dispensed using a D300 digital dispenser (Hewlett-
Packard, Tecan Trading AG, Switzerland). After 72 h
treatment of the cells, resazurin (Sigma-Aldrich Chemie
Gmbh, Munich, Germany) was added and relative fluores-
cence was measured using a plate reader (Tecan Spark 10
M, Tecan Trading AG, Switzerland) at 530–570 nm (exci-
tation), and at 590–620 nm (emission). Synergy scores were
calculated using Synergy Finder web application (https://
synergyfinder.fimm.fi).
2D MTS assay
A total of 3000–4000 cells/well was plated overnight in 96-
well flat bottomed plates. Next day, cells were exposed to
either TH1579 for 72 h after which MTS solution (Promega,
Madison, WI, USA) was added and absorbance at 490 nm
was measured using Tecan Spark 10M plate reader (Tecan
Trading AG, Switzerland) to determine the inhibitory con-
centration of the drugs according to the manufacturer’s
protocol.
3D MTS assay using tumor sphere growth with the
hanging drop method
Approximately 10,000 cells/well were pipetted into conical
well ULA plates (Corning art. 7007, Sigma-Aldrich Chemie
Gmbh, Munich, Germany) in DMEM medium. To each
well with 200 µl media and cells, additional medium was
added to overfill the wells. Lids were attached using spacers
to allow room for the hanging drops before turning the
plates. Plates were shaken at 300 rpm with amplitude of 3
mm on a lab shaker (Thermo Scientific, Waltham, MA,
USA) at 37 °C in cell incubator overnight. Plates were
turned back, excess media removed, and the spheres were
left to mature for 3–5 days, before being treated with single
drug for 72 h. 3D MTS solution CellTiter 3D (Promega,
Madison, WI, USA) was added according to the
manufacturer’s protocol. The plate was wrapped in alumi-
num foil and mixed at 30 rpm on a laboratory rocker
(Thermo Fisher Scientific, Waltham, MA, USA) for cell
lysis (30 min at 37 °C). Fifty microliters of the lysate were
read on a luminescence plate for ATP determination in
Tecan Spark 10M microplate reader (Tecan Trading AG,
Switzerland) and drug efficacy on viability. CDI values
were calculated as for the 2D viability assays.
Colony formation assay
A total of 1000 cells/well were plated into six-well plates
overnight. Cells were treated with either DMSO or 0.9 µM
TH1579 for 5 days, with media change after every 2 days.
Colonies were allowed to form for an additional 7 days in
absence of the drug, with the media being replaced every
3 days. Cells were after 12 days fixed for 20 min using 4 %
buffered formaldehyde. Colonies were stained with 0.05%
crystal violet solution for 10 min followed by two washes
with 1X PBS. Stained plates were scanned using Epson
scanner V370. For estimation of the number of colonies
formed, crystal violet was dissolved in 100% methanol,
transferred to a 96-well plate, diluted 1:10 using PBS and
absorbance was measured at 540 nm using Tecan Spark 10
M plate reader instrument.
ROS measurement
A total of 50,000 cells/well were incubated overnight in 12-
well plates. For ROS measurements, cells were either left
untreated or were treated with TH1579 (0.5 or 0.9 µM) or,
PLX4032 (0.45 µM) or the combination, trypsinzed and
stained with CM-H2DCF (Life Technologies, C8627) and
analyzed by FACS as per the manufacturer’s protocol.
Modified comet assay
The modified comet assay was performed as earlier
described [16]. Briefly, cells were seeded into six-well
plates at a density of 150,000–200,000 cells per well and
the day after treated for 24 h. Cells were then harvested by
trypsinization and washed with 1X PBS, resuspended in
1X PBS at a concentration of approximately one million
cells/ml. Cell suspension was mixed with 1.2 % low
melting agarose and the mixture was added over to 1%
agarose coated fully frosted slides. The slides were
incubated in lysis buffer containing [100 mM sodium
EDTA, 2.5 mM NaCl, 10 mM Tris–HCl (pH 10)], 1%
Triton X-100 and 10% DMSO 2 h at room temp in the
dark. After incubation, slides were washed three times
with enzyme buffer containing KCl, Hepes, EDTA, and
BSA followed by addition of OGG1 enzyme and incu-
bated at 37 °C for 45 min. At the end of incubation period
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alkaline denaturation with alkali buffer (300 mM NaOH,
1 mM sodium EDTA) was carried out in an electrophor-
esis chamber for 20 min. Electrophoresis was run at 25 V
and 300 mA in the same buffer for 30 min. The slides
were later neutralized with neutralizing buffer [250 mM
Tris–HCl (pH 7.5)] for 45 min. Just before imaging, the
slides were stained with 1X SYBR gold dye. One hundred
comets were account using Comet IV software.
Immunoblotting
For western blots, cells were lysed on ice using RIPA buffer
(25 mM Tris•HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1%
sodium deoxycholate, 0.1% SDS), 1 mM NaOV, protease
and phosphatase inhibitors for 30 min and vortexed every
10 min followed by centrifugation and protein measurement
using BCA kit as per the manufacturer’s protocol. Protein
was loaded on NuPage 4–12% Bis-Tris gel (Thermo Fisher
Scientific, Waltham, MA, USA) and transferred into a
PVDF membrane. Membranes were blocked in 5% BSA
and incubated overnight with primary antibodies followed
by incubation with secondary antibodies detected by ECL
reagent using Image Quant LAS 4000 (GE Healthcare
Europe GmbH, Freiburg, Germany).
Immunofluorescence
Cryosections using zebrafish embryos were made as pre-
viously described [30]. For immunostaining on cryosec-
tions, the slides were equilibrated in 1X PBS-Tween 20 for
three washes, 5 min each, and then blocked with 10%
donkey serum (ab 7475) or goat serum (ab 7481) in 1X
PBS-Tween 20 for 1 h at room temperature. After blocking,
the slides were incubated overnight at 4 °C with either anti-
CAV-1 (1:400) or anti-AXL (1:100). Next day, the slides
were washed in 1X PBS-Tween 20 for three washes, 5 min
each with minimal shaking (50 rpm). They were incubated
with secondary antibody (1:500) for 2 h followed by 1X
PBS-Tween 20 washes for three times, 5 min each. The
slides were then mounted using DAPI fluoroshield (F6057)
and imaged by AxioImager M2 (Zeiss).
Time-lapse microscopy
A total of 700–1200 cells/well either single or in co-culture
were plated in a 96-well black plate with transparent bottom,
treated with DMSO or PLX4032 (0.4 µM) or Trametinib
(3 nM) or TH1579 (0.45, 0.9, 1.8 µM) and incubated at
37 °C in 95% humidified atmosphere with 5% CO2. The
plates were imaged at 10X using time-lapse microscopy
(ImageXpress MicroXL (Molecular Devises)) between days
0 and 4 at a regular interval of 24 h. Images were then
exported and quantified using cell profiler analyst software.
The cell numbers were calculated based on staining the cells
with DAPI. All cell numbers for each group were normal-
ized to the cell count for that group on day 0.
RNA extraction
Cell line RNA extraction was performed using the product
manual using the AllPrep DNA/RNA/miRNA kit (Qiagen,
Hilden, Germany). RNA quantity and quality measurements
were performed using Agilent Bioanalyzer 2100 instrument
(Agilent Technologies Inc., Santa Clara, CA, USA).
Real-time PCR
The extracted RNA was converted to cDNA in a 20 µl
reaction using standard reagents from Invitrogen with
SuperScript III reverse transcriptase (Carlsbad, CA, USA).
The cDNA was diluted fourfold with ddH2O and subjected
to semiquantitative real-time PCR reaction in a Bio-Rad
CFX instrument (Hercules, CA, USA). The real-time PCR
results were analyzed in CFX Manager software.
Extraction of data from targeted sequencing using
Ion AmpliSeq™
Targeted sequencing of fine needle aspirate or core biopsy
RNA from metastases and RNA from cell lines was pre-
viously performed using the Ion AmpliSeq Transcriptome
Human Gene Expression Kit for RefSeq genes ((Thermo
Fisher Scientific, Waltham, MA. USA) as described in [27].
Data on mRNA abundance of our candidates of interest
were extracted from the normalized transcript using the
reads per kilobase per million reads method.
Co-immunoprecipitation assay
Cells were plated at 85% confluency and allowed to grow
overnight. The following day, the cells were collected and
protein was extracted on ice using cell lysis buffer (cell sig-
naling, #9803) with protease and phosphatase supplements
and protein amount was quantified using BCA as previously
described. A total of 300 µg of protein was mixed with pre-
washed magnetic beads (Thermo Scentific, #88802) and pri-
mary antibody (concentration used as per the manufacturer’s
recommendation) and incubated overnight at 4 °C. The fol-
lowing day, beads were washed again to remove unbound
antibody, boiled with 4X SDS (Thermo Scientific, #NP0007)
and analyzed using western blot.
In vitro kinase assay
A total of 384-well, white, low volume, nonbinding plates
(Costar #3824) were nanodispensed with dose–response
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curves of test compounds. The AXL kinase reaction
(V3961, Promega) was performed using 1× reaction buffer,
containing 50 µM DTT, including AXL kinase (1.2 µg/mL),
AXLtide substrate (0.2 mg/mL), and ATP (50 µM) in a total
volume of 5 µl/well and a reaction time of 60 min at room
temperature followed by the ADP-Glow assay (V9101,
Promega) where 5 µl/well of ADP-Glo reagent was added
and plate was incubated at room temperature for 40 min
after which 10 µl/well of kinase detection reagent was added
followed by 30 min incubation at room temperature.
Luminescence was recorded in Hidex Sense reader.
CETSA-western blot
CETSA (Cellular Thermal Shift Assay) was performed as
previously described in [31]. Briefly, cells were plated
overnight to 70% confluency. The following day, cells were
treated with DMSO or TH1579 (0.9 µM) for 2 h at 37 °C
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followed by trypsinization and resuspension in media. A
total of 80 µl of cells were added to a PCR tube per heating
condition and heat treated for 3 min (Veriti 96-well thermal
cycler, AB). Samples were then lysed using RIPA buffer
with required supplements. Samples were stored at −80 °C,
until further analysis by western blot.
In situ PLA
In situ PLA was run using Duolink In situ PLA Sigma-
Aldrich (according to the manufacturer’s protocol). Briefly,
the cells were permeabilized in 0.5% Triton X-100 in TBS
for 5 min followed by washing in TBST (TBS+ 0.05%
Tween 20). Blocking was performed overnight. Antibody
(primary) incubation was performed O/N. After PLA the
cells were stained with 1:40 Phalloidin for 15 min at room
temperature and mounted with mounting medium contain-
ing DAPI. Cells were then analyzed using florescence
microscope (Zeiss) and subsequently the PLA signal was
measured using cell profiler software.
Lot Numbers:
Antibody diluent: SLBT2003/SLBX5745.
Blocking solution: SLBV6065.
Anti rabbit minus probe: Cat No DUO82005 lot nr
SLBX3145.
Anti rabbit plus probe: Cat No DUO82002 lot nr
SLBT8716.
Anti mouse plus probe: Cat no DUO82001 lot no
SLBV2113.
Anti mouse minus probe Cat no DUO82004 lot no
SLBS7468.
Statistical analysis
All experiments were performed in triplicate and repre-
sentative results were presented where data were expressed
as mean ± SD or mean ± SEM as mentioned in figure
legends. Variance between groups statistically compared
was similar. All statistical analyses were carried out using
GraphPad Prism v.7.0 (GraphPad Software, La Jolla, CA,
USA). Two-tailed student’s t test or two-way ANNOVA
test was used to compare the difference between groups. For
comparing patient survival data, Mantel–Cox log rank test
was employed. For all other comparisons between patient
groups, Mann–Whitney U test was used.
Results
Sensitivity to TH1579 is independent of BRAF/NRAS
mutational background
Given that ROS and oxidative stress has been suggested to
drive CMM development and MTH1 sanitizes oxidized
nucleotides, we wanted to see if MTH1 levels correlated with
prognosis of CMM. Analysis of the TCGA dataset revealed
that CMM patients with higher mRNA levels of MTH1
(greater than twofold) exhibit a shorter disease-free survival
(p= 0.053) (Supplementary Fig. S1a) and a significantly
shorter overall survival (p < 0.001) (Fig. 1a), suggesting a role
of MTH1 as a prognostic marker for CMM.
To investigate whether the BRAF/NRAS mutational
background of CMM influences the response to TH1579,
CMM cells were exposed for 72 h and cell viability was
measured. The inhibitory concentration at 50% (IC50)
showed a variation from 0.23 to 1.4 µM (Supplementary
Table S1a). BRAFi resistant cell lines had the highest IC50
values when compared with the remaining cell lines (Fig. 1b
and Supplementary Table S1).
The cytotoxic effects of TH1579 were confirmed in a
spheroid model system (Fig. 1c, d). A primary patient-derived
cell line 159-Pre (BRAF WT) also responded very well to
TH1579 treatment (Fig. 1e). TH1579 significantly reduced
tumor growth as well as the levels of Ki67 in a zebrafish model
(p < 0.01) without showing general toxicity at the concentration
tested (Fig. 1f–h and Supplementary Fig. S1b, c).
Fig. 1 CMM cells are sensitive to MTH1 inhibitor TH1579 inde-
pendent of BRAF/NRAS mutational status. a High MTH1 mRNA
expression significantly decreases overall survival in CMM patients (n
= 460) (data analyzed from TCGA). b Cell viability measured by
MTS following 72 h treatment with TH1579 shows that NRAS, BRAF
mutated and WT CMM are sensitive to TH1579 treatment. CMM cells
with acquired or intrinsic resistance to vemurafenib have higher IC50
values for TH1579. (Error bars represent mean ± SEM; n= 3). c
Representative images taken before (day 0) and after 72 h (day 3) of
treatment showing the effects of 2 µM TH1579 on CMM spheroid
compared with control (DMSO) treated spheroids. d After 72 h treat-
ment with 0, 0.5, 1, 2 or 4 µM TH1579, the cell viability of the
spheroids were measured by CellTiterGlo. (Error bars represent mean
± SD; n= 3, ***p < 0.001, two-way ANNOVA test). e Short-term
patient-derived cell line, 159-Pre (BRAF WT) was cultured as spher-
oids and treated with TH1579 at concentrations shown in the figure.
After 72 h treatment, cell viability was measured by CellTiterGlo.
(Error bars represent mean ± SD; n= 3, ***p < 0.001, two-way
ANNOVA test). f Schematic illustration of the experimental model
of CMM transplanted zebrafish embryo disease model used in this
study. Briefly, ~100 CMM cells stably expressing tdTomato and
luciferase were injected into blastula of zebrafish embryo. The next
day, embryos were screened for successful transplantation, and dis-
tributed into six-well plates (15 embryos/well). TH1579 was added
directly to the medium to a final concentration of 20 or 40 μM. After
72 h, individual embryos were lysed and amount of CMM cells (i.e.,
tumor volume) were measured by luminescence. g TH1579 (20 μM)
significantly reduces tumor volume in CMM transplanted zebrafish
embryo disease model. Tumor size calculated as % of reduction of
DMSO control. Data shown as mean ± SD from n= 4 independent
experiments (Error bars represent mean ± SD, **p < 0.01, ***p <
0.001, ****p < 0.0001, Student’s t test). h Loss of Ki67 signal shown
by IF of zebrafish embryo sections transplanted with SkMel2 collected
after 72 h treatment with TH1579 (20 µM).
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Heterogenous CMM co-cultures are sensitive to
TH1579 treatment
Tumor intra- and inter-heterogeneity is common in CMM
and heterogeneity presents itself as a resistance mechanism.
To recapitulate this in vitro, we established a system where
we labeled each cell line with a different fluorescent protein,
and divided them into a “BRAF set” or a “NRAS set”
(Fig. 2a). ESTDAB105 grow slower than the BRAF/NRAS
cells and therefore the ratio was adjusted based on
respective cell lines proliferation rate. After 4 days of co-
culturing, the majority of the “BRAF set” culture consisted
of the A375VR4 in the control (DMSO) group as well as
after treatment with trametinib and vemurafenib (Fig. 2b).
Interestingly, the proportions of the various cells following
treatment with TH1579 were similar to prior treatment
(Fig. 2b), indicating that TH1579 was equally potent in
killing the CMM cells. After 4 days of co-culturing of the
“NRAS set” similar proportions of CMM cells could be
observed day 4 as day 0 following vemurafenib or trame-
tinib treatment (Fig. 2c). TH1579 treatment was more
effective in hindering SkMel2 proliferation as the propor-
tion of this cell line was lower at day 4 compared with day 0
(Fig. 2c).
TH1579 was equally or more effective than vemur-
afenib and trametinib in killing cells in co-culture as well
as individually cultured cells when analyzing surviving
fractions by using FACS (Fig. 2d and Supplementary
Fig. S2).
We also cultured 3D spheroids using our labeled cell
lines, A375 and A375VR4, and compared the differences in
response with TH1579 either when co-cultured or cultured
alone. The effects were documented at 24 and 72 h, show-
ing significant reduction of 3D spheroids independent
whether co-cultured or cultured alone (Fig. 2e, f).
TH1579 mediates loss of cell viability mainly
through induction of apoptosis
To determine whether the reduced cell viability and growth
inhibition was a result of apoptosis, five cell lines with
different BRAF/NRAS mutational status were selected and
treated with TH1579 for 24 and 48 h, respectively. The
IC50 of the BRAFi (vemurafenib) resistant subline,
A375VR4, was chosen as the concentration used. FACS
analysis demonstrated that CMM cells underwent apoptosis
already after 24 h (Supplementary Fig. S3a) which was
further enhanced after 48 h of treatment (Fig. 2g). The
induction of apoptosis after 48 h for BRAF (~50–75% (p <
0.001)) and NRAS mutant lines (~50–75% (p < 0.001)) was
higher than for BRAF/NRAS WT cell line ESTDAB105
(25% (p < 0.001)) (Fig. 2g).
TH1579 treatment led to G2/M arrest in ESTDAB105
(p < 0.0001) (Supplementary Fig. S3b, c), followed by a
significant decrease in cell proliferation as assessed by
fewer colonies being formed (p < 0.0001) (Supplementary
Fig. S3d, e). A similar G2/M arrest was also observed in the
BRAF/NRAS WT cell line ESTDAB138 (Supplementary
Fig. S3f). By using time-lapse microscopy, we observed a
significant prolonged time in mitosis following TH1579
treatment in both A375 and A375VR4 cells, resulting in
polynucleation and apoptosis (Fig. 2h–j, Movie MV1–
MV4).
Fig. 2 TH1579 treatment causes prolonged time in mitosis and cell
death in co-culture (NRAS and BRAF sets) as well as in 3D
spheroid culture of CMM cells. a Schematic illustration of single and
co-culture experiments to compare drug sensitivity. Briefly, A375 and
SkMEl2 cells were tagged with eGFP (green), A375VR4 and EST-
DAB102 with mTagBFP (blue) and ESTDAB105 with mKO2 (red).
Cells were then either single cultured or co-cultured as BRAF set
(A375, A375VR4, and ESTDAB105) or NRAS set (SkMel2, EST-
DAB102, and ESTDAB105) overnight before treatment with DMSO
or BRAF inhibitor (Vemurafenib, Vem, 0.4 μM), MEK inhibitor
(Trametinib, Tram, 3 nM), or MTH1 inhibitor (TH1579, 0.45 μM) for
4 days. Time-lapse microscopy was performed to detect changes in
cell proliferation by measuring number of cells (DAPI count) followed
by quantification using cell profiler software. The proportion of each
CMM cell line (shown in b and c) was calculated as % of total number
of cells day 0 (i.e., before treatment) and day 4 (i.e., following 4 days
treatment), respectively. FACS was performed on day 0, 2, and 4 to
measure fraction of apoptotic cells (measured as a ratio of number of
labeled+AnnV+ cells to total number of labeled+ cells). b For the
BRAF set, the BRAFi resistant A375VR4 cell approximately doubled
its proportion after 4 days in control (DMSO), vemurafenib as well as
trametinib treated cells. TH1579 treated co-culture showed almost no
change in cell proportions day 4 compared with day 0. c For the NRAF
set, TH1579 was particularly effective in stopping proliferation of
SkMel2, since the proportion of SkMel2 went from 30% day 0 to 11%
day 4, as compared with the proportion of control treated co-culture
from 30% day 0 to 38% day 4. d FACS analysis shows that BRAF
mutant and NRAS mutant CMM cells retain their sensitivity towards
TH1579 either when cultured separately or in a co-culture system
(error bars represent mean ± SD; n= 3, *p < 0.05, **p < 0.01, ***p <
0.001, ****p < 0.000, Student’s t test). Data shown as ratio of number
of Annexin V labeled cells to total number of labeled cells for each cell
line (i.e., fraction of survival cells) either co-cultured or as cultured
separately, before treatment (day 0), and treatment day 2 and 4. e
Representative images of A375 and A375VR4 spheroids treated with
DMSO (control) or TH1579 (2 µM) for 72 h (n= 3). f Representative
images of spheroid co-culturing of A375 with its vemurafenib resistant
subline A375VR4 before and following DMSO (control) or TH1579
(2 µM) for 72 h (n= 3). g Treatment with TH1579 triggers cell death
via induction of apoptosis. CMM cells were treated for 48 h with 0.9
µM TH1579 and analyzed by Annexin V+ stain and PI+ stain
(FACS) (error bars represent mean ± SD; n= 3, *p < 0.05, **p < 0.01,
***p < 0.001, ****p < 0.000, Student’s t test). h Histone labeling
followed by time-lapse microscopy analysis shows that A375 and
A375VR4 CMM cells treated with lower doses of TH1579 (250 nM
and 500 nM) display a significantly prolonged mitotic phase (M) fol-
lowed by mitotic slippage and polynucleation (MS/PN), micronuclei
(G1/MN), mitotic slippage (MS) and death in mitosis (DiM). i
Representative Images from time-lapse experiment in h. j Quantifi-
cation of of the time in mitosis in h. (error bars represent mean ± SD; n
= 2, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, Student’s
t test).
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TH1579 causes induction of ROS and DNA damage
in CMM cells
To investigate if ROS levels can influence CMM cells
response to TH1579 treatment we measured ROS by using
a H2DCFDA assay. Baseline levels of ROS demonstrated
differences between the cell lines with SkMel2 having the
highest basal ROS levels (Fig. 3a–b). The ROS levels were
most pronouncedly induced upon short treatment (3 h) with
0.9 µM TH1579 (p < 0.01) in A375VR4 and SkMEl2
(Fig. 3c). There was no significant increase in ROS levels
for ESTDAB105 (Supplementary Fig. S3g), which may
explain why apoptosis was lower in this cell line (Fig. 2g).
There was a significant correlation observed between ROS
induction and induced apoptosis with r= 0.95 and p < 0.05
(Fig. 3d). There was no significant correlation between
MTH1 protein levels at baseline and baseline ROS (Fig. 3f).
SkMel2, one of the cell lines with high sensitivity to
TH1579, also had high MTH1 protein levels (Fig. 3e).
Treatment for 24 h with TH1579 did not reduce the
MTH1 protein levels (Fig. 3g), indicating that TH1579 did
not inhibit the translation of the protein. TH1579 induced
elevated levels of DNA damage marker (p-H2AX) in all
CMM cells tested (Fig. 3g). This induction was most pre-
dominant in A375VR4 which also had a higher baseline of
p-H2AX. Confirming previous findings (Fig. 2d), cleaved
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Fig. 3 TH1579 induces ROS leading to increased DNA damage in
CMM cells. a FACS plot showing differences in baseline ROS levels
across CMM cells as measured by H2DCFA counts. b Quantification
of a (error bars represent mean ± SD; n= 3). c CMM cells treated for
3 h with TH1579 (0.9 µM) displays elevated ROS levels using
H2DCFA assay (error bars represent mean ± SD; n= 3; *p < 0.05,
**p < 0.01, ***p < 0.001, ns: not significant, Student's t test). d
TH1579 induced ROS (data shown in c) is positively correlated with
percentage of apoptosis (data obtain in Fig. 2g) after drug treatment. e
Representative image from western blot showing baseline MTH1
expression levels in CMM cells. f A positive trend, however not
significant, is found between baseline MTH1 expression (data obtained
from e) and ROS levels (data obtained from b) in CMM cells. g
Representative image of western blot showing that 24 h treatment with
0.9 µM TH1579 (n= 3) increases p-H2AX signal (DNA damage
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Representative images of modified comet assay in CMM cells (A375,
A375VR4, and ESTDAB102) treated with TH1579 (0.9 µM) and
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(control) and with OGG1 to identify 8-oxodG. i Quantification of h
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0.001, Student’s t test).
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caspase 3 was upregulated in all cell lines, except EST-
DAB105 (Fig. 3g and Supplementary Fig. S3h). TH1579
treatment also induced 8-oxo-dG incorporation in CMM
cells as measured with a modified comet assay (Fig. 3h, i).
Silencing MTH1 alone exhibits cytotoxic effects in
most CMM cell lines
To determine the importance of MTH1 as a target in CMM,
we knocked down MTH1 using an inducible shRNA based
approach. MTH1 knockdown caused induction of cleaved
caspase 3, significant induction of cell death and reduced
ability to form colonies in three out of four cell lines tested,
while there was no effect on A375VR4 (p < 0.1)
(Fig. 4a–d). Surprisingly, despite no effect on cell survival,
the MTH1 knockdown in A375VR4 induced elevated DNA
damage markers (Fig. 4e), showed a tendency to increase
ROS (Fig. 4f) and a slight prolonged time in mitosis
(Fig. 4g–i, Movie MV5, MV6). As observed with TH1579,
MTH1 knockdown in A375 cells significantly prolonged
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time in mitosis (Fig. 4j–l) and significantly elevated ROS
levels (Fig. 4f).
CMM cells with high AXL are more sensitive to
TH1579 treatment
Since it is known that ROS activates RTKs [32, 33], we
wanted to investigate if RTKs play a role in TH1579 mode
of action. Based on the results obtained from a pRTK array
screen upon treating A375, A375VR4, SkMel2, and EST-
DAB105 for 24 h with 0.9 µM TH1579 (data not shown)
and a previously published study [31], we decided to further
investigate TH1579 induced effects on AXL, EPHA2,
EGFR, IGF1R, MET and some downstream effectors. AXL
and EPHA2 (A375VR4 and SkMel2), EGFR and IGF1R
(A375 and A375VR4), MET were downregulated (Fig. 5a
and Supplementary S4a) upon exposure to TH1579.
Downstream effectors JNK1 and AKT were downregulated
after 24 h exposure to TH1579 in A375 and A375VR4 and
after 48 h in SkMEl2, whereas pERK was significantly
downregulated only in A375 (Fig. 5a–h and Supplementary
Fig. S4a, b). We focused on AXL since it has been sug-
gested to have an impact on both BRAF targeted and DNA
damaging therapies [20, 24]. A consistent downregulation
of AXL and AKT expression was observed in longer term
cultures (48 h) of both A375VR4 and SkMel2 (Supple-
mentary Fig. S4c).
To determine if the change of AXL following TH1579
treatment was an early event, A375VR4 and SkMel2 were
exposed to TH1579 for 1, 3, and 6 h. In A375VR4, a
decrease of AXL was observed at 6 h, whereas in SkMel2
there was a reduction of AXL already at 3 h. (Fig. 5b and
Supplementary Fig. S4d). These changes were most likely
occurring posttranslationally, since mRNA levels of AXL
was unchanged (Supplementary Fig. S4e). Downregulation
of AXL by TH1579 was also confirmed in CMM xeno-
grafted zebrafish models (Supplementary Fig. S5a). Using
an in vitro kinase assay, we showed that TH1579 did not
inhibit AXL activity (Supplementary Fig. S5b), indicating
that the downregulation of AXL is a downstream effect of
TH1579 and not a direct target of the drug.
Correlation analysis revealed that there was a positive
trend, although not significant, between basal AXL mRNA
expression and apoptosis induction by TH1579 (r= 0.801,
p= 0.1) (Fig. 5c). To confirm that high levels of AXL make
the cells more prone to respond to TH1579 treatment, we
overexpressed AXL in cell lines with low AXL expression
(Fig. 5d). Indeed, AXL induction significantly increased
inhibitor mediated cell death in both A375 and EST-
DAB105 (p < 0.01) (Fig. 5e), highlighting that AXL may
play an important role in determining the sensitivity of
CMM cells towards TH1579.
Since ROS induction in turn induces AXL in a ligand
independent fashion [34], we next sought out to find if AXL
overexpression can induce ROS levels and thereby make
the cells more sensitive to a MTH1 inhibitor. We observed
that AXL overexpression increased ROS levels by around
50% in both A375 and ESTDAB105 (Fig. 5f). Interestingly,
a positive trend, though not significant (p= 0.2) was
observed between the ratio of AXL and MTH1 in our
matched clinical samples from CMM patients (Fig. 5g).
A network analysis (http://www.networkanalyst.ca/) was
performed on the RTKs whose expression was altered upon
24 h treatment with TH1579. The results indicated that
different gene ontologies were affected including regulation
of apoptosis, stress response, cell cycle, and cell migration.
Furthermore, KEGG analysis showed that CMM was the
most significantly altered disease associated with changes in
RTKs and MTH1 (Supplementary Fig. S6).
Inhibition of CAV-1 leads to decreased response to
TH1579 in BRAF inhibitor resistant cell line A375VR4
From previous studies in our lab [27], we know that
A375VR4 has high expression of CAV-1 mRNA (Supple-
mentary Table S2). TCGA analysis shows that AXL,
MTH1, and CAV-1 have a higher alteration frequency for
Fig. 4 Knockdown of MTH1 in CMM cells, excluding BRAF
inhibitor resistant subline A375VR4, sensitizes cells towards cell
death. a A representative image from western blot of MTH1 knock-
down in CMM cell lines. Two different shRNAs were used (sh2 and
sh3) and compared with control (NT). Knockdown of MTH1 induces
cleaved caspase 3 in all cell lines tested except A375VR4 (n= 2
independent experiments). b shMTH1 induces apoptosis measured by
FACS (Annexin V) in A375, SkMel2, and ESTDAB105, but not in
A375VR4 CMM cells. (error bars represent mean ± SD; n= 3; *p <
0.05, **p < 0.01, ***p < 0.001, Student's t test). c Representative
images from clonogenic survival following shRNA MTH1 knockdown
(sh2 and sh3) or control (NT) in CMM cell lines. d Quantification of c
by measuring absorbance at 540 nm as a readout. (error bars represent
mean ± SD; n= 3; *p < 0.05, **p < 0.01, ***p < 0.001, Student's t
test). e Knockdown of MTH1 (sh2, sh3) in A375VR4 cells followed
by western blot shows that the knockdown can cause induction of
DNA damage (p21 and p-H2AX S139) for both shRNA sequences
tested when compared with the nontargeting control shRNA. (western
blot is a representative image of n= 2). f ROS levels measured by
H2DCFA assay following MTH1 knockdown (sh2) or control (NT) in
A375 cells and A375VR4. (error bars represent mean ± SD; n= 3; *p
< 0.05, **p < 0.01, ***p < 0.001, Student's t test). g Representative
images from time-lapse microscopy following doxycycline-induced
knockdown (shMTH1 dox) of MTH1 or control (shNT dox and
shMTH1 no dox) in A375VR4 cells. h, i Quantification of g. MTH1
knockdown (doxycycline-induced shRNA) in A375VR4 cells show no
change of time in mitosis (error bars represent mean ± SD; n= 2, *p <
0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). j Representative
images from time-lapse microscopy following doxycycline-induced
knockdown (shMTH1 dox) of MTH1 or control (shNT dox and
shMTH1 no dox) in A375 cells. k, l Quantification of j. MTH1
knockdown (doxycycline-induced shRNA) in A375 cells induce sig-
nificantly prolonged time in mitosis (p < 0.01) (error bars represent
mean ± SD; n= 2; ***p < 0.001, Student's t test).
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increased mRNA expression (Supplementary Fig. S7a). Our
cohort of samples from targeted and immunotherapy (n=
32) show slightly elevated median levels of AXL expres-
sion in nonresponders to targeted therapy (Supplementary
Fig. S7b). Furthermore, TCGA analysis revealed that CAV-
1 mRNA expression is increased in patients with disease
stage I-IV vs stage 0 (Supplementary Fig. S7c). However,
we did not find any correlation between AXL-MTH1 and
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CAV-1-MTH1 with regards to the stage of the disease
(Supplementary Fig. S7d, e).
Interestingly, we observed that both p-CAV-1 and total
CAV-1 expression was reduced in A375VR4 after TH1579
treatment (Fig. 5h). Using CETSA, we observed no direct
target engagement of TH1579 to CAV-1 (Supplementary
Fig. S8a), indicating that the observed reduction of CAV-1
levels is a downstream effect of the treatment. Interestingly,
when CAV-1 was downregulated, the TH1579-mediated
apoptosis in A375VR4 was significantly abolished (Fig. 5i).
However, knocking down MTH1 alone in A375VR4 did not
downregulate CAV-1 (Fig. 5j) while silencing of CAV-1 led to
downregulation of both AXL and MTH1, which may explain
the loss of effect by TH1579. (Supplementary Fig. S8b).
Co-IP experiments showed a weak interaction between
CAV-1 and MTH1 in A375VR4 (Supplementary Fig. S9a).
In contrast, no protein–protein interaction between MTH1-
AXL was found (Supplementary Fig. S9b, c). To further
verify our observation, we performed PLA analysis, con-
firming that CAV-1 interacted with MTH1 (Fig. 5k, l).
Downregulation of CAV-1 expression in our in vivo zeb-
rafish model further corroborated that TH1579 inhibits
CAV-1 expression (Fig. 5m). We also observed a positive
correlation between MTH1 and CAV-1 expression in clin-
ical samples taken pretreatment (Fig. 5n).
Combining BRAF inhibitors to TH1579 further
sensitizes BRAF mutant cells
To investigate whether the combination of BRAFi and
TH1579 could further potentiate the killing of BRAF mutant
CMM cells we used a proliferation assay. We observed that
the combination of vemurafenib or dabrafenib with
TH1579 significantly reduced cell proliferation and induced
cell death (p < 0.01) in A375, A375VR4, and ESTDAB049
cell lines compared with either treatment alone (Fig. 6a, b
and Supplementary Fig. S10). We observed that the com-
bination treatment of vemurafenib and TH1579 induced
more ROS than either treatment alone (Fig. 6c and Sup-
plementary Fig. S10). Furthermore, the combination treat-
ment reduced the tumor size in the zebrafish by 3.5- and 4-
fold in A375 and A375VR4, respectively (p < 0.05)
(Fig. 6d, e). Interestingly, the combination downregulated
AXL, CAV-1, and AKT when compared with single
treatment arms or DMSO control in both cell lines (Fig. 6f,
g), which may explain the improved efficacy observed in
the combination treatment compared with monotherapy
with TH1579.
Discussion
The significance of ROS for the treatment effect as well as
resistance development cannot be underestimated in CMM-
a tumor type heavily laden with ROS. It has been postulated
that DNA repair proteins play a vital role in maintaining
overall cellular homeostasis by maintaining ROS levels
[35]. One such player is MTH1, which cancer cells often
use as a major defense mechanism to eliminate elevated
intracellular ROS. We now identify TH1579, a potent
inhibitor of MTH1, as a highly efficacious drug to treat
CMM by not solely inhibiting MTH1, but also through
downregulation of key proteins in BRAFi resistance path-
ways, like AXL and CAV-1. These changes are con-
comitant with increased incorporation of damaged
nucleotides, increase in intracellular ROS and mitotic arrest
(Fig. 7).
Fig. 5 AXL and CAV-1 mediate sensitivity of CMM cells towards
TH1579. a Representative image of western blot without (−) and with
(+) 24 h treatment of 0.9 µM TH1579 in CMM cells. b Short-term (1,
3, and 6 h) treatment with TH1579 (0.3 and 0.9 µM) downregulates
AXL in AXL overexpressing CMM cells as seen in representative
image of western blot. c Cells with higher AXL mRNA expression
have tendency to be more sensitive to TH1579. Data are obtained from
Figs. 2g and 5a and plotted as correlation between AXL expression
(normalized to loading control) and % apoptosis (Annexin V staining,
FACS). d AXL overexpression was done in CMM cells with endo-
genous low AXL. The image is a representative western blot from n=
2 independent experiments. e Overexpression of AXL triggers sensi-
tivity towards TH1579. Overexpression was done in CMM cells with
low AXL (A375, ESTDAB105) for 24 h followed by 24 h treatment
with 0.9 µM TH1579 and apoptosis measured by using FACS staining
for Annexin V+, PI+. (error bars represent mean ± SD; n= 3; *p <
0.05, **p < 0.01, ***p < 0.001, Student's t test). f ROS measurement
by H2DCFDA assay confirms that ROS is induced in both cell lines
upon AXL overexpression (O.E) compared with control cells. (error
bars represent mean ± SD; n= 3; *p < 0.05, **p < 0.01, ***p < 0.001,
Student's t test). g Ratio of AXL and MTH1 expression correlate
positively, although not significant (r= 0.64, p= 0.2) in CMM
patients on comparing matched pretreatment samples to those taken
during treatment (immunotherapy or targeted therapy) (n= 5). h
Representative western blot image of n= 2 independent experiments.
CAV-1 which is highly expressed in A375VR4 is downregulated after
24 h treatment with 0.9 µM TH1579 compared with control treated
cells. Also MET and JNK1 (MAPK8) are downregulated compared
with control cells. i Knockdown of CAV-1 (siRNA#1 and #4)
decreases TH1579 sensitivity as analyzed by Annexin V staining using
FACS in A375VR4 CMM cells (error bars represent mean ± SD; n=
3; *p < 0.05, **p < 0.01, ***p < 0.001, Student's t test). j shMTH1
(sh2 and sh3) does not reduce CAV-1 expression in A375VR4.
Contrary to the inhibitor, knockdown of MTH1 alone does not
decrease CAV-1 expression levels as seen by western blot (Data
shown as a representative western blot image, n= 2). k Proximity
Ligation Assay (PLA) shows CAV-1 and MTH1 interact in A375VR4.
Analysis by PLA indicates that MTH1 and CAV-1 interacts only in
A375VR4 and not in A375 or SKMel2. Data shown as a representative
image, n= 2. l Quantification of (K) (error bars represent mean ± SD;
n= 2; *p < 0.05, **p < 0.01, ***p < 0.001, Student's t test). m Treat-
ment with TH1579 (20 µM) decreases expression of CAV-1 in an
A375VR4 zebrafish disease model as seen by IF. n CAV-1 expression
correlates to MTH1 expression in CMM patients both in responders to
targeted and immunotherapy (n= 25). Sample set previously used in
[44] (*p < 0.05, Student's t test).
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MTH1 loss has previously been shown to selectively
eradicate cells with high levels of RAS and ROS [36]. Our
results corroborate that excessive ROS led to elevated
apoptosis following TH1579 treatment, but the effect was
independent of BRAF/NRAS mutations (Figs. 1 and 2 and
Supplementary Fig. S2). This was in line with previous
findings in CMM mice xenograft models [37] and may be
explained by a general high basal ROS level detected in WT
as well as BRAF/NRAS mutated CMM cells (Fig. 3b).
Recent studies show on one hand that MTH1 is an
important target for cancer [14, 15, 37], whereas on the
other hand some studies claim MTH1 inhibition to be
nontoxic, thereby questioning the anticancer therapeutic
potential of MTH1i [38, 39]. We reported that mitotic
arrest, elevated ROS and 8-oxodGTP are important for the
efficacy of TH1579 and that noncytotoxic MTH1i can show
synergistic effects when combined with mitotic arrest
agents [40]. Emerging evidence connect mitotic arrest with
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Fig. 6 Combination treatment of TH1579 with vemurafenib
(PLX4032) further sensitizes BRAF mutant CMM cells both
in vitro and in vivo. a 72 h treatment of BRAF mutant cells A375 and
A375VR4 with the combination TH1579 (0.2 µM) and vemurafenib
(0.1 µM) leads to further loss of cell viability as measured by an MTS
assay when compared with either drug alone (error bars represent
mean ± SD; n= 3; *p < 0.05, Student's t test). b The loss of cell via-
bility observed in a translates into apoptosis mediated cell death which
is further enhanced by the drug combination (treatment done for 48 h)
as analyzed by FACS and Annexin V staining (error bars represent
mean ± SD; n= 3; *p < 0.05, Student’s t test). c Combining vemur-
afenib with TH1579 significantly induces ROS levels (treatment done
for 3 h) when compared with either drug alone (error bars represent
mean ± SD; n= 3; *p < 0.05, Student's t test). d Representative images
taken by microscopy to show A375 (stably expressing dTomato) and
A375VR4 (stably expressing eGFP) tumors in zebrafish disease model
after 72 h drug exposure with DMSO, vemurafenib (20 µM), TH1579
(20 µM) or the combination. e Individual tumor sizes from zebrafish
embryos were analyzed after lysing zebrafish and measure lumines-
cence. Data presented as % tumor size compared with the median
tumor size calculated for that group (error bars represent mean ± SD; n
= 3; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, Student's t
test). f, g CAV-1, AXL, and AKT are most efficiently downregulated
by combination treatment following 48 h treatment. Representative
western blot image (f) and densiometric quantification of the western
blot (g) (data shown as mean ± SD, n= 2).
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ROS. For instance, it has been shown that the level of ROS
changes with cell cycle, where ROS is increased during
mitosis and a mitotic arrest further enhances ROS levels
[41]. Whether MTH1 directly alter ROS levels and plays a
role during mitosis is still under debate. Here, we observe
that knockdown of MTH1 in A375, but not in A375VR4,
significantly prolonged time in mitosis with a concomitant
increase in ROS levels resulting in cell death (Fig. 4), thus
suggesting that MTH1 may directly influence ROS level
and play a role in mitosis in A375 cells. One explanation to
the discrepancy in A375 and A375VR4 MTH1 knockdown
could be that the knockdown in A375VR4 cells was not as
successful as in the other CMM cells. Other plausible
explanations could be that some dNTP sanitizing enzymes
may compensate for the loss in MTH1 activity [42] or that
CAV-1 silencing is essential to stimulate cytotoxic effects
in these cells as shown in this study (Fig. 5).
Limited duration of efficacy of therapy modules have
often been attributed to upregulation of RTK signaling
which is caused by the high phenotypic plasticity of CMMs.
We have shown that TH1579 is able to downregulate sev-
eral key RTKs associated with therapy resistance including
AXL (Fig. 5 and Supplementary Figs. S4 and S5). More-
over, we have also shown that CMM cells with high AXL
are more sensitive to TH1579 inhibitor. Recent studies
indicate that CAV-1 has several other functions beyond
protein transport like its role in signal transduction, tumor
progression and tumor regression and also that KRAS
inhibits MTH1 function through CAV-1 [43]. We have
confirmed a weak interaction between CAV-1 and MTH1 in
BRAFi resistant CMM cells (Fig. 5 and Supplementary
Fig. S9). Our results suggest a novel mode of regulation
involving CAV-1 and MTH1 where CAV-1 positively
modulates TH1579 cytotoxicity (Fig. 5 and Supplementary
Figs. S8 and 9).
The current strategy of treatment employing targeted
therapy for CMM patients with BRAF mutation is the
combination of BRAFi and MEKi [1]. To this end, we have
also highlighted that combining TH1579 together with
BRAFi might be an attractive therapy regime of choice
BRAF mutant, BRAFi sensitive CMM BRAF mutant, BRAFi resistant CMM
NRAS mutant CMM Overexpressing AXL in WT and 
BRAF mutant, inhibitor sensitive CMM
A B
C D
Fig. 7 Schematic illustration how TH1579 downregulates AXL
and CAV-1 expression and induces ROS, leading to DNA damage
and cell death. a In BRAF mutant CMM, TH1579 treatment inhibits
MTH1, elevates ROS, causes a mitotic arrest, DNA damage and
reduced AKT signaling. Combining BRAF inhibitor vemurafenib and
TH1579 results in additive/synergistic responses by affecting several
pathways leading to apoptosis and cell death. b BRAF inhibitor
resistant CMM have upregulated levels of AXL and CAV-1, resulting
in overactivated MAPK signaling overriding the effect of BRAF
inhibitor. In addition to the effects of TH1579 observed in BRAF-
mutated CMM, TH1579 downregulates AXL and CAV-1 levels,
resulting in improved efficacy of BRAF inhibitor treatment. c NRAS
mutated CMM has upregulated AXL compared with BRAF mutated
and WT CMM and TH1579 treatment reduces the level of AXL,
hinder AKT signaling, induces ROS, causes DNA damage, mitotic
arrest and cancer cell death. d By overexpressing AXL in WT and
BRAF-mutated CMM, increased ROS levels and improved efficacy
following TH1579 treatment was observed.
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since our study showed that the combination could enhance
cell killing both in vitro and in vivo.
Herein, we show that CMM cells are sensitive to
TH1579, independent of BRAF/NRAS mutational status. We
unveil important correlations between AXL and CAV-1,
highlighting their role in determining overall sensitivity of
CMM cells towards TH1579 treatment. Importantly, we are
the first one to report that induction of AXL is able to
induce cellular ROS levels. Lastly, we show that combining
BRAFi with TH1579 was more potent than the single drugs.
TH1579 (Karonudib) is presently investigated in a clinical
Phase 1 trial in patients with advanced solid malignancies
(www.clinicaltrial.gov//MASTIFF). We envision TH1579
as a promising alternate therapy for CMM patients where
AXL and CAV-1 may be potential predictive biomarkers.
Combining TH1579 with other drugs would enhance the
clinical applicability of TH1579.
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